Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Aug;66(2):361–366. doi: 10.1038/bjc.1992.271

Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer.

E J Wawrzynczak 1, U Zangemeister-Wittke 1, R Waibel 1, R V Henry 1, G D Parnell 1, A J Cumber 1, M Jones 1, R A Stahel 1
PMCID: PMC1977812  PMID: 1323991

Abstract

An immunotoxin (IT) comprising abrin A chain attached to the mouse monoclonal antibody SWA11, recognising a cell surface antigen highly associated with human small cell lung cancer (SCLC), was synthesised using a hindered disulphide crosslinker, N-succinimidyl 3-(2-pyridyldithio) butyrate (SPDB), and purified by Blue Sepharose CL-6B affinity chromatography. The IT preparation contained monomeric conjugate, composed of one abrin A chain molecule linked to one SWA11 molecule, and was free from unconjugated A chain or antibody. The IT fully retained the cell-binding capacity of the antibody component and the ribosome-inactivating activity of the A chain. In cytotoxicity assays using the SW2 SCLC cell line in tissue culture, SWA11-SPDB-abrin A chain inhibited the incorporation of 3H-leucine by 50% at a concentration of 10 pM and by 99% at a concentration of 1 nM. The anti-tumour efficacy of the IT was tested in nude mice bearing established s.c. solid SW2 tumour xenografts. A single i.v. injection of SWA11-SPDB-abrin A chain at a non-toxic dose induced a significant 7 to 10 day growth delay that could not be matched by administration of equivalent doses of either unconjugated SWA11 or abrin A chain alone. The results of this study indicate that the antigen recognised by SWA11 is an effective target for therapy of SCLC with A chain ITs in vivo.

Full text

PDF
361

Images in this article

362Figure 1
on p.362

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cumber A. J., Forrester J. A., Foxwell B. M., Ross W. C., Thorpe P. E. Preparation of antibody-toxin conjugates. Methods Enzymol. 1985;112:207–225. doi: 10.1016/s0076-6879(85)12018-5. [DOI] [PubMed] [Google Scholar]
  2. Derbyshire E. J., Wawrzynczak E. J. Monoclonal antibodies recognising the cluster 2 antigen associated with human small cell lung cancer mediate the toxic effects of ricin A chain in an indirect assay of immunotoxin cytotoxicity. Br J Cancer Suppl. 1991 Jun;14:74–77. [PMC free article] [PubMed] [Google Scholar]
  3. Forrester J. A., McIntosh D. P., Cumber A. J., Parnell G. D., Ross W. C. Delivery of ricin and abrin A-chains to human carcinoma cells in culture following covalent linkage to monoclonal antibody LICR-LOND-Fib 75. Cancer Drug Deliv. 1984 Fall;1(4):283–292. doi: 10.1089/cdd.1984.1.283. [DOI] [PubMed] [Google Scholar]
  4. Hwang K. M., Foon K. A., Cheung P. H., Pearson J. W., Oldham R. K. Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen. Cancer Res. 1984 Oct;44(10):4578–4586. [PubMed] [Google Scholar]
  5. Knowles P. P., Thorpe P. E. Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue sepharose CL-6B. Anal Biochem. 1987 Feb 1;160(2):440–443. doi: 10.1016/0003-2697(87)90073-x. [DOI] [PubMed] [Google Scholar]
  6. Olsnes S., Refsnes K., Christensen T. B., Pihl A. Studies on the structure and properties of the lectins from Abrus precatorius and Ricinus communis. Biochim Biophys Acta. 1975 Sep 9;405(1):1–10. doi: 10.1016/0005-2795(75)90308-6. [DOI] [PubMed] [Google Scholar]
  7. Sivam G., Pearson J. W., Bohn W., Oldham R. K., Sadoff J. C., Morgan A. C., Jr Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates. Cancer Res. 1987 Jun 15;47(12):3169–3173. [PubMed] [Google Scholar]
  8. Skilleter D. N., Price R. J., Parnell G. D., Cumber A. J. The low uptake of an abrin A-chain immunotoxin by rat hepatic cells in vivo and in vitro. Cancer Lett. 1989 Aug;46(3):161–166. doi: 10.1016/0304-3835(89)90125-0. [DOI] [PubMed] [Google Scholar]
  9. Smith A., Groscurth P., Waibel R., Westera G., Stahel R. A. Imaging and therapy of small cell carcinoma xenografts using 131I-labeled monoclonal antibody SWA11. Cancer Res. 1990 Feb 1;50(3 Suppl):980s–984s. [PubMed] [Google Scholar]
  10. Smith A., Waibel R., Stahel R. A. Selective immunotherapy of small cell cancer xenografts using 131I-labelled SWA11 antibody. Br J Cancer. 1991 Aug;64(2):263–266. doi: 10.1038/bjc.1991.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Smith A., Waibel R., Westera G., Martin A., Zimmerman A. T., Stahel R. A. Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11. Br J Cancer. 1989 Feb;59(2):174–178. doi: 10.1038/bjc.1989.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Thorpe P. E., Blakey D. C., Brown A. N., Knowles P. P., Knyba R. E., Wallace P. M., Watson G. J., Wawrzynczak E. J. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants. J Natl Cancer Inst. 1987 Nov;79(5):1101–1112. [PubMed] [Google Scholar]
  13. Thorpe P. E., Wallace P. M., Knowles P. P., Relf M. G., Brown A. N., Watson G. J., Blakey D. C., Newell D. R. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res. 1988 Nov 15;48(22):6396–6403. [PubMed] [Google Scholar]
  14. Wawrzynczak E. J., Cumber A. J., Henry R. V., May J., Newell D. R., Parnell G. D., Worrell N. R., Forrester J. A. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin. Cancer Res. 1990 Dec 1;50(23):7519–7526. [PubMed] [Google Scholar]
  15. Wawrzynczak E. J., Cumber A. J., Henry R. V., Parnell G. D. Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A1 chain and recombinant ricin A chain. Int J Cancer. 1991 Jan 2;47(1):130–135. doi: 10.1002/ijc.2910470123. [DOI] [PubMed] [Google Scholar]
  16. Wawrzynczak E. J., Derbyshire E. J., Henry R. V., Parnell G. D., Smith A., Waibel R., Stahel R. A. Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen. Br J Cancer. 1990 Sep;62(3):410–414. doi: 10.1038/bjc.1990.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wawrzynczak E. J. Systemic immunotoxin therapy of cancer: advances and prospects. Br J Cancer. 1991 Oct;64(4):624–630. doi: 10.1038/bjc.1991.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wood K. A., Lord J. M., Wawrzynczak E. J., Piatak M. Preproabrin: genomic cloning, characterisation and the expression of the A-chain in Escherichia coli. Eur J Biochem. 1991 Jun 15;198(3):723–732. doi: 10.1111/j.1432-1033.1991.tb16072.x. [DOI] [PubMed] [Google Scholar]
  19. Worrell N. R., Cumber A. J., Parnell G. D., Mirza A., Forrester J. A., Ross W. C. Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats. Anticancer Drug Des. 1986 Nov;1(3):179–188. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES